Skip to main content
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results Press Releases

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

SAN DIEGO, March 04, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives, reported financial results for the three months and full year ended December 31, 2019, and provided an update on its corporate activities and product pipeline. "2019 was a transformational year for Cidara, as we achieved multiple key corporate and clinical milestones," said Jeffrey Stein, Ph.D., president and chief executive officer…
wpengine
March 4, 2020
Cidara Therapeutics to Present at Transplantation & Cellular Therapy (TCT) and Mycology 2020 Medical Conferences Press Releases

Cidara Therapeutics to Present at Transplantation & Cellular Therapy (TCT) and Mycology 2020 Medical Conferences

SAN DIEGO, Feb. 18, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapeutics to improve the standard of care for patients facing severe fungal or viral infections, today announced that it will present a poster at the Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR), which takes place from Feb. 19-23, 2020, in…
wpengine
February 18, 2020
Cidara Therapeutics Announces Closing of Rights Offering Press Releases

Cidara Therapeutics Announces Closing of Rights Offering

SAN DIEGO, Feb. 12, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) ("Cidara") today announced the closing of its previously announced rights offering (the "Rights Offering"). At the closing, Cidara sold and issued an aggregate of 6,639,307 shares of its common stock (the "Common Stock") and an aggregate of 531,288 shares of its Series X convertible preferred stock ("Series X Preferred Stock"), pursuant to the exercise of subscription rights in the Rights Offering from its existing…
wpengine
February 12, 2020
Cidara Therapeutics Announces Commencement of Rights Offering Press Releases

Cidara Therapeutics Announces Commencement of Rights Offering

SAN DIEGO, Jan. 22, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) ("Cidara") today commenced the previously announced rights offering to raise gross proceeds of approximately $30.0 million (the "Rights Offering"). Under the terms of the Rights Offering, the holders, as of 5:00 p.m., New York time, on January 21, 2020, of Cidara's common stock and Series X convertible preferred stock, and Cidara's warrants issued on May 21, 2018, are entitled to purchase up to 11,952,191…
wpengine
January 22, 2020
Cidara Therapeutics Announces Proposed Rights Offering Press Releases

Cidara Therapeutics Announces Proposed Rights Offering

Rights Offering will be available to all stockholders and 2018 warrant holders of record on January 21, 2020 $30.0 million to be raised, fully backstopped SAN DIEGO, Jan. 10, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) ("Cidara") today announced its intent to raise $30.0 million through a fully backstopped rights offering. Under the terms of the rights offering, investors as of January 21, 2020 in Cidara's common stock and preferred stock, as well as the…
wpengine
January 10, 2020
Cidara Therapeutics to Present at Two Upcoming Medical Conferences Press Releases

Cidara Therapeutics to Present at Two Upcoming Medical Conferences

ASH presentation will include new preclinical data on rezafungin for prevention of PneumocystisSAN DIEGO, Dec. 03, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present a poster at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, which takes place Dec 7-10, 2019, in Orlando, Fl, and will deliver an oral presentation at the 39th Interdisciplinary Meeting on Anti-Infective Chemotherapy, which…
wpengine
December 3, 2019
Cidara Therapeutics Named a San Diego Metro Area Top Workplace for the Third Consecutive Year Press Releases

Cidara Therapeutics Named a San Diego Metro Area Top Workplace for the Third Consecutive Year

Employee feedback places Cidara among top small companies in the areaSAN DIEGO, Nov. 18, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a Top Workplace by The San Diego Union-Tribune for the third consecutive year. Cidara was the top life sciences company and only biotech included in the small company category in the San Diego Metro Area. "It is a great…
wpengine
November 18, 2019
Cidara Provides Corporate Update and Reports Third Quarter 2019 Financial Results Press Releases

Cidara Provides Corporate Update and Reports Third Quarter 2019 Financial Results

SAN DIEGO, Nov. 07, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2019 and provided an update on its corporate activities and product pipeline. "The last several months represent a truly transformative period for Cidara. Our partnership with Mundipharma validated the significant commercial potential of rezafungin and provides financial and other resources that enable us to continue…
wpengine
November 7, 2019
Cidara Therapeutics Hosting Key Opinion Leader Meeting on Rezafungin and Cloudbreak Programs Press Releases

Cidara Therapeutics Hosting Key Opinion Leader Meeting on Rezafungin and Cloudbreak Programs

SAN DIEGO, Nov. 05, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will host a Key Opinion Leader (KOL) meeting on its rezafungin and Cloudbreak programs on November 14 in New York City for institutional investors, sell-side analysts, and business development professionals. The meeting will feature presentations from Key Opinion Leaders, Neil J. Clancy, M.D. (University of Pittsburgh), Kieren Marr, M.D. (Johns Hopkins University…
wpengine
November 5, 2019
Cidara Therapeutics to Present New Clinical and Preclinical Data at Two Upcoming Medical Conferences Press Releases

Cidara Therapeutics to Present New Clinical and Preclinical Data at Two Upcoming Medical Conferences

SAN DIEGO, Oct. 03, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present three posters at the Infectious Diseases Society of America (IDSA) IDWeek 2019, which takes place October 2-6, 2019, in Washington, D.C., and four posters, including a late-breaking poster, at the 9th Trends in Medical Mycology (TIMM), which takes place October 11-14, 2019, in Nice, France. The presentations at IDWeek will…
wpengine
October 3, 2019
Skip to content